Biotech Unusual Volume: Agios Pharmaceuticals (NASDAQ:AGIO), OHR (NASDAQ:OHRP), La Jolla (NASDAQ:LJPC), Aastrom Biosciences (NASDAQ:ASTM)

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Monday, Analyst Ratings News reports. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was 2.84% in last session and finished the day at $46.74. Traded volume was 983,271 million shares in the last session and the average volume of the stock remained … Continue reading Biotech Unusual Volume: Agios Pharmaceuticals (NASDAQ:AGIO), OHR (NASDAQ:OHRP), La Jolla (NASDAQ:LJPC), Aastrom Biosciences (NASDAQ:ASTM)

Biotech Most Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Northwest Biotherapeutics (NASDAQ:NWBO), Peregrine Pharmaceuticals (NASDAQ:PPHM), MannKind (NASDAQ:MNKD)

Inovio Pharmaceuticals, Inc. (AMEX:INO) entered into an office lease (the “Lease”) with a publicly owned real estate investment trust, located in Plymouth Meeting, Pennsylvania. We expect to occupy the space commencing in the third quarter of 2014. The initial term of the lease is eleven and one-half years. We intend to use the facility for office purposes. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was 3.53% … Continue reading Biotech Most Active Stocks: Inovio Pharmaceuticals (NYSEMKT:INO), Northwest Biotherapeutics (NASDAQ:NWBO), Peregrine Pharmaceuticals (NASDAQ:PPHM), MannKind (NASDAQ:MNKD)

CytRx Corporation (NASDAQ:CYTR) on Mar. 5 reported financial results for the 12 months ended December 31, 2013, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) stock performance was -4.14% in last session and finished the day at $5.10. Traded volume was 3,687,994 million shares in the last session and the average volume of the … Continue reading Biotech Most Volatile: CytRx Corporation (NASDAQ:CYTR), Merrimack Pharmaceuticals (NASDAQ:MACK), CEL-SCI Corporation (NYSEMKT:CVM), IGI Laboratories (NYSEMKT:IG)

An increase in European and U.S. sales helped Reliv International Inc. (NASDAQ:RELV) raise profits by a small amount in the fourth quarter. Reliv International, Inc (NASDAQ:RELV) stock performance was -11.60% in last session and finished the day at $2.03. Traded volume was 64,448.00million shares in the last session and the average volume of the stock remained 10.29K shares. The beta of the stock remained 1.35. … Continue reading Biotech Stocks Touching New Lows: Reliv International (NASDAQ:RELV), Can Fite Biopharma (NYSEMKT:CANF), Enzymotec (NASDAQ:ENZY), Pacific Biosciences (NASDAQ:PACB)

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on Mar. 3 announced the appointment of Mark P. Carthy to the company’s Board of Directors. Mr. Carthy is the Managing Partner of Orion Equity Partners, LLC, a healthcare venture capital management and advisory firm co-founded by Mr. Carthy in 2008. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock performance was -5.68% in last session and finished the day at $1.25. Traded volume was … Continue reading Biotech Top Losers: Rexahn Pharmaceuticals (NYSEMKT:RNN), Aegerion Pharmaceuticals (NASDAQ:AEGR), Enzymotec Ltd (NASDAQ:ENZY), Can Fite Biopharma (NYSEMKT:CANF)

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was a big mover last session, as its shares rose nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the healthcare company since Feb 24, as the stock is now down nearly 19%. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) dropped -5.53 percent to $52.46 … Continue reading Biotech Top Losers: Rexahn Pharmaceuticals (NYSEMKT:RNN), Aegerion Pharmaceuticals (NASDAQ:AEGR), Enzymotec Ltd (NASDAQ:ENZY), Can Fite Biopharma (NYSEMKT:CANF)